Therapeutic Utility of NK3 Receptor Antagonists for the Treatment of Schizophrenia

E-ISSN： 1873-4286|16|3|344-357

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.16, Iss.3, 2010-01, pp. : 344-357

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development and Potential Utility of Dual and Triple NK Receptor Antagonists

Current Topics in Medicinal Chemistry, Vol. 3, Iss. 12, 2003-08 ,pp. : 1410-1422

Bentham Science Publishers

Access to resources Recommend Favorite

Serotonin 2A receptor antagonists for treatment of schizophrenia

By Ebdrup Bjøørn H Rasmussen Hans Arnt Jøørn Glenthøøj Birte

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 9, 2011-09 ,pp. : 1211-1223

Informa Healthcare

Access to resources Recommend Favorite

A role of tachykinin NK 2 receptor antagonists in the treatment of IBS?

By Lecci A.

Trends in Pharmacological Sciences, Vol. 22, Iss. 11, 2001-11 ,pp. : 551-552

Elsevier

Access to resources Recommend Favorite

A New Frontier in the Treatment of Cancer: NK-1 Receptor Antagonists

Current Medicinal Chemistry, Vol. 17, Iss. 6, 2010-02 ,pp. : 504-516

Bentham Science Publishers

Access to resources Recommend Favorite

Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?

Current Pharmaceutical Design, Vol. 21, Iss. 26, 2015-01 ,pp. : 3760-3770

Bentham Science Publishers

Access to resources Recommend Favorite